Global Beyond the Pill 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08246120

Publication Date:

August 21, 2024

Pages:

110

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Beyond the pill refers to a shift in the pharmaceutical industry towards providing holistic healthcare services and products that go beyond traditional drug-based treatments. The term "beyond the pill" emphasizes the need for pharmaceutical companies to provide additional support and services to patients beyond simply prescribing medications.Beyond the pill offerings can include a wide range of products and services, such as patient education programs, digital health technologies, medical devices, and patient monitoring services. The goal of these offerings is to improve patient outcomes and satisfaction while also providing additional revenue streams for pharmaceutical companies.
The global Beyond the Pill market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淏eyond the Pill Industry Forecast鈥� looks at past sales and reviews total world Beyond the Pill sales in 2023, providing a comprehensive analysis by region and market sector of projected Beyond the Pill sales for 2024 through 2030. With Beyond the Pill sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Beyond the Pill industry.
This Insight Report provides a comprehensive analysis of the global Beyond the Pill landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Beyond the Pill portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Beyond the Pill market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Beyond the Pill and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Beyond the Pill.
The beyond the pill market has seen significant growth in recent years, driven by factors such as the increasing importance of patient-centered care, the rise of digital health technologies, and the growing demand for value-based healthcare. Key players in the beyond the pill market include major pharmaceutical companies such as Pfizer, Roche, Novartis, and Sanofi, as well as a number of smaller startups and technology companies.
The beyond the pill market is expected to continue to grow as more pharmaceutical companies recognize the importance of providing holistic healthcare solutions and as patients continue to demand more personalized and integrated care.
This report presents a comprehensive overview, market shares, and growth opportunities of Beyond the Pill market by product type, application, key players and key regions and countries.
Segmentation by type
Services
Monitoring
Assistance
Segmentation by application
Diabetes
Oncology
Cardiovascular Diseases
Asthma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
Sanofi S.A
Novo Nordisk A/S
Eli Lilly and Company
F. Hoffmann-La Roche AG (Flatiron Health)
Otsuka Pharmaceuticals Co., Ltd
Amgen, Inc.
AstraZeneca Plc
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Beyond the Pill 麻豆原创 Size 2019-2030
2.1.2 Beyond the Pill 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Beyond the Pill Segment by Type
2.2.1 Services
2.2.2 Monitoring
2.2.3 Assistance
2.3 Beyond the Pill 麻豆原创 Size by Type
2.3.1 Beyond the Pill 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Beyond the Pill 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Beyond the Pill Segment by Application
2.4.1 Diabetes
2.4.2 Oncology
2.4.3 Cardiovascular Diseases
2.4.4 Asthma
2.4.5 Other
2.5 Beyond the Pill 麻豆原创 Size by Application
2.5.1 Beyond the Pill 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Beyond the Pill 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Beyond the Pill 麻豆原创 Size by Player
3.1 Beyond the Pill 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Beyond the Pill Revenue by Players (2019-2024)
3.1.2 Global Beyond the Pill Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Beyond the Pill Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Beyond the Pill by Regions
4.1 Beyond the Pill 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Beyond the Pill 麻豆原创 Size Growth (2019-2024)
4.3 APAC Beyond the Pill 麻豆原创 Size Growth (2019-2024)
4.4 Europe Beyond the Pill 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Beyond the Pill 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Beyond the Pill 麻豆原创 Size by Country (2019-2024)
5.2 Americas Beyond the Pill 麻豆原创 Size by Type (2019-2024)
5.3 Americas Beyond the Pill 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Beyond the Pill 麻豆原创 Size by Region (2019-2024)
6.2 APAC Beyond the Pill 麻豆原创 Size by Type (2019-2024)
6.3 APAC Beyond the Pill 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Beyond the Pill by Country (2019-2024)
7.2 Europe Beyond the Pill 麻豆原创 Size by Type (2019-2024)
7.3 Europe Beyond the Pill 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Beyond the Pill by Region (2019-2024)
8.2 Middle East & Africa Beyond the Pill 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Beyond the Pill 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Beyond the Pill 麻豆原创 Forecast
10.1 Global Beyond the Pill Forecast by Regions (2025-2030)
10.1.1 Global Beyond the Pill Forecast by Regions (2025-2030)
10.1.2 Americas Beyond the Pill Forecast
10.1.3 APAC Beyond the Pill Forecast
10.1.4 Europe Beyond the Pill Forecast
10.1.5 Middle East & Africa Beyond the Pill Forecast
10.2 Americas Beyond the Pill Forecast by Country (2025-2030)
10.2.1 United States Beyond the Pill 麻豆原创 Forecast
10.2.2 Canada Beyond the Pill 麻豆原创 Forecast
10.2.3 Mexico Beyond the Pill 麻豆原创 Forecast
10.2.4 Brazil Beyond the Pill 麻豆原创 Forecast
10.3 APAC Beyond the Pill Forecast by Region (2025-2030)
10.3.1 China Beyond the Pill 麻豆原创 Forecast
10.3.2 Japan Beyond the Pill 麻豆原创 Forecast
10.3.3 Korea Beyond the Pill 麻豆原创 Forecast
10.3.4 Southeast Asia Beyond the Pill 麻豆原创 Forecast
10.3.5 India Beyond the Pill 麻豆原创 Forecast
10.3.6 Australia Beyond the Pill 麻豆原创 Forecast
10.4 Europe Beyond the Pill Forecast by Country (2025-2030)
10.4.1 Germany Beyond the Pill 麻豆原创 Forecast
10.4.2 France Beyond the Pill 麻豆原创 Forecast
10.4.3 UK Beyond the Pill 麻豆原创 Forecast
10.4.4 Italy Beyond the Pill 麻豆原创 Forecast
10.4.5 Russia Beyond the Pill 麻豆原创 Forecast
10.5 Middle East & Africa Beyond the Pill Forecast by Region (2025-2030)
10.5.1 Egypt Beyond the Pill 麻豆原创 Forecast
10.5.2 South Africa Beyond the Pill 麻豆原创 Forecast
10.5.3 Israel Beyond the Pill 麻豆原创 Forecast
10.5.4 Turkey Beyond the Pill 麻豆原创 Forecast
10.5.5 GCC Countries Beyond the Pill 麻豆原创 Forecast
10.6 Global Beyond the Pill Forecast by Type (2025-2030)
10.7 Global Beyond the Pill Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Novartis AG
11.1.1 Novartis AG Company Information
11.1.2 Novartis AG Beyond the Pill Product Offered
11.1.3 Novartis AG Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Novartis AG Main Business Overview
11.1.5 Novartis AG Latest Developments
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Information
11.2.2 Sanofi S.A Beyond the Pill Product Offered
11.2.3 Sanofi S.A Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Sanofi S.A Main Business Overview
11.2.5 Sanofi S.A Latest Developments
11.3 Novo Nordisk A/S
11.3.1 Novo Nordisk A/S Company Information
11.3.2 Novo Nordisk A/S Beyond the Pill Product Offered
11.3.3 Novo Nordisk A/S Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Novo Nordisk A/S Main Business Overview
11.3.5 Novo Nordisk A/S Latest Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Information
11.4.2 Eli Lilly and Company Beyond the Pill Product Offered
11.4.3 Eli Lilly and Company Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Eli Lilly and Company Main Business Overview
11.4.5 Eli Lilly and Company Latest Developments
11.5 F. Hoffmann-La Roche AG (Flatiron Health)
11.5.1 F. Hoffmann-La Roche AG (Flatiron Health) Company Information
11.5.2 F. Hoffmann-La Roche AG (Flatiron Health) Beyond the Pill Product Offered
11.5.3 F. Hoffmann-La Roche AG (Flatiron Health) Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 F. Hoffmann-La Roche AG (Flatiron Health) Main Business Overview
11.5.5 F. Hoffmann-La Roche AG (Flatiron Health) Latest Developments
11.6 Otsuka Pharmaceuticals Co., Ltd
11.6.1 Otsuka Pharmaceuticals Co., Ltd Company Information
11.6.2 Otsuka Pharmaceuticals Co., Ltd Beyond the Pill Product Offered
11.6.3 Otsuka Pharmaceuticals Co., Ltd Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Otsuka Pharmaceuticals Co., Ltd Main Business Overview
11.6.5 Otsuka Pharmaceuticals Co., Ltd Latest Developments
11.7 Amgen, Inc.
11.7.1 Amgen, Inc. Company Information
11.7.2 Amgen, Inc. Beyond the Pill Product Offered
11.7.3 Amgen, Inc. Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Amgen, Inc. Main Business Overview
11.7.5 Amgen, Inc. Latest Developments
11.8 AstraZeneca Plc
11.8.1 AstraZeneca Plc Company Information
11.8.2 AstraZeneca Plc Beyond the Pill Product Offered
11.8.3 AstraZeneca Plc Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 AstraZeneca Plc Main Business Overview
11.8.5 AstraZeneca Plc Latest Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Information
11.9.2 Johnson & Johnson Beyond the Pill Product Offered
11.9.3 Johnson & Johnson Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Johnson & Johnson Main Business Overview
11.9.5 Johnson & Johnson Latest Developments
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Information
11.10.2 Teva Pharmaceutical Industries Ltd. Beyond the Pill Product Offered
11.10.3 Teva Pharmaceutical Industries Ltd. Beyond the Pill Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.10.5 Teva Pharmaceutical Industries Ltd. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.